RaySearch Laboratories is pleased to announce that RayStation, its advanced treatment planning system, was used in the first European clinical treatments with Neutron Therapeutics’ accelerator-based boron neutron capture therapy, carried out on a patient at Helsinki University Hospital in Finland.
RayStation supports BNCT planning by its suite of tools for patient modelling, plan setup and plan evaluation. In addition, there are specific adaptations for use with the Neutron Therapeutics machine including seamless connection to the BNCT dose engine provided by Neutron Therapeutics.
Health Technology Insights: Olio Launches Referral and Care Coordination for Skilled Nursing Operators
RayStation’s BNCT capabilities have now been clinically proven in both Japanese and Finnish healthcare environments. The platform’s flexibility and precision support individualized treatment planning and ensure optimal dose delivery, a critical requirement for BNCT where dose localization is vital to treatment success.
The treatments were successfully conducted using Neutron Therapeutics’ nuBeam Suite, which integrates the neutron source, imaging, positioning, and treatment planning powered by RayStation. The Comprehensive Cancer Center at Helsinki University Hospital, with over 30 years of BNCT experience, is the first European center to deploy this technology. The patients treated are the first in an ongoing clinical trial aimed at demonstrating the safety and efficacy of BNCT for patients with inoperable, locally recurrent head and neck cancer.
Health Technology Insights: CareRev Expands Workforce Platform to Support Allied Healthcare Professionals
Mikko Tenhunen, Chief Medical Physicist, Head of Division, Professor, the Comprehensive Cancer Center, Helsinki University Hospital, says: “BNCT is a very promising tool for obtaining new treatment options for the most challenging tumor types. With the comprehensive treatment planning software from RaySearch and dose calculation engine from Neutron Therapeutics we are able to, as the first center in the world, deliver image guided, 3D planned BNCT for our patients.”
Noah Smick, President and COO, Neutron Therapeutics, says: “RaySearch has been an invaluable partner in the establishment of in-hospital BNCT in Europe and Asia. We are proud to offer BNCT solutions incorporating BNCT treatment planning with RayStation and look forward to continued collaboration to expand access to BNCT globally.”
Johan Löf, founder and CEO, RaySearch, says: “We are proud to see RayStation in use at the forefront of BNCT clinical development, now in both Asia and Europe. Our collaboration with Helsinki University Hospital and Neutron Therapeutics is part of our work to improve cancer treatment through innovative technology and partnerships.”
Health Technology Insights: Ouro Medicines Launches OM336 Trial for Autoimmune Cytopenias
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
